This white paper explores how synthetic advisory boards can help pharmaceutical teams generate timely, scalable insights for launch planning, evidence strategy, and market access. These AI-enabled environments use digital twins representing different healthcare stakeholders to test evidence, messages, objections, and strategic scenarios rapidly. They are designed to complement, not replace, traditional advisory boards, which remain essential for expert judgment, human nuance, and relationship building. Synthetic boards can pressure test more hypotheses, identify potential blind spots, and improve the focus of live discussions. Their effectiveness depends on healthcare-grade data, domain-specific AI agents, workflow integration, transparent reasoning, uncertainty flags, and continued human

Join for free to read